In this study, we demonstrated that the TJ107 treatment in the MCAO mice decreased astrocyte proliferation that leads to the extent of gliosis (glial scarring) around the lesion, with decreased GFAP expression at 70 days after the onset of cerebral infarction, the chronic phase of ischemic stroke, accompanied with anti-inflammatory effects through TNF-α suppression. The gene discussed is GFAP; the disease is brain infarction.